GlassScriptPhysician profile
Steven Hodgkin
NPI 1780675587
$4,126.94
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $691 · 2021: $972 · 2022: $1,124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.67 | 2019-2022 | |
| Leo Pharma INC. | $537.72 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $415.73 | 2019-2022 | |
| Pfizer INC. | $372.93 | 2019-2022 | |
| Genzyme Corporation | $342.79 | 2019-2022 | |
| Ucb, INC. | $337.26 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $239.74 | 2020-2022 | |
| Janssen Biotech, INC. | $208.60 | 2019-2022 | |
| Genentech USA, INC. | $132.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $113.87 | 2020-2022 | |
| Lilly USA, LLC | $106.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $76.01 | 2019 | |
| Almirall LLC | $75.47 | 2022 | |
| Lumenis, INC | $68.19 | 2021 | |
| Allergan, INC. | $53.82 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $52.24 | 2019 | |
| Epi Health, LLC | $51.06 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.39 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $42.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.15 | 2021 | |
| Organogenesis INC. | $32.55 | 2020 | |
| Merz North America, INC. | $21.25 | 2020 | |
| Biofrontera INC. | $14.08 | 2019 | |
| Prugen, INC. Pharmaceuticals | $13.08 | 2019 | |
| Nabriva Therapeutics, Plc | $12.82 | 2021 | |
| Galderma Laboratories, L.P. | $11.04 | 2020 | |
| Strata Skin Sciences, INC. | $10.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hodgkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.